Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 1 of 1 for:    NCT03127618
Previous Study | Return to List | Next Study

Lorlatinib - PF-06463922

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03127618
Expanded Access Status : Available
First Posted : April 25, 2017
Last Update Posted : September 30, 2019
Information provided by (Responsible Party):

Tracking Information
First Submitted Date April 20, 2017
First Posted Date April 25, 2017
Last Update Posted Date September 30, 2019
Descriptive Information
Brief Title Lorlatinib - PF-06463922
Official Title Not Provided
Brief Summary

Information relating to requesting compassionate access for this investigational drug can be found at the following link:

Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Not Provided
Intervention Drug: Lorlatinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Eligibility Criteria

Inclusion Criteria:

  • Adult, Senior

Exclusion Criteria:


Sex/Gender Not Provided
Ages 18 Years and older   (Adult, Older Adult)
Contact: Pfizer CAReS 1-800-718-1021
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03127618
Other Study ID Numbers B746
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators Not Provided
PRS Account Pfizer
Verification Date September 2019